- Home
- ALLT vs ENTA Comparison
ALLT vs ENTA Comparison
Compare ALLT & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLT | ENTA |
|---|---|---|
| Founded | 1996 | 1995 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.1M | 486.3M |
| IPO Year | 2006 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ALLT | ENTA |
|---|---|---|
| Price | $9.80 | $15.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $12.75 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 401.2K | 377.0K |
| Earning Date | 11-20-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $98,512,000.00 | $65,324,000.00 |
| Revenue This Year | $12.08 | $0.99 |
| Revenue Next Year | $12.38 | $0.19 |
| P/E Ratio | $456.22 | ★ N/A |
| Revenue Growth | ★ 7.51 | N/A |
| 52 Week Low | $4.37 | $4.09 |
| 52 Week High | $11.42 | $17.15 |
Technical Indicators
Market Signals| Indicator | ALLT | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 57.35 | 60.04 |
| Support Level | $9.06 | $14.07 |
| Resistance Level | $9.95 | $17.15 |
| Average True Range (ATR) | 0.40 | 0.95 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 67.71 | 56.71 |
Price Performance
Historical ComparisonAbout ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.